These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25098174)

  • 1. Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin.
    Gesheff MG; Franzese CJ; Bliden KP; Contino CJ; Rafeedheen R; Tantry US; Gurbel PA
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):645-53. PubMed ID: 25098174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
    Peura DA; Wilcox CM
    Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
    Zhang W; Han Y; Fort JG; Schofield D; Tursi JP
    J Med Econ; 2017 Jun; 20(6):592-598. PubMed ID: 28145783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
    Sylvester KW; Cheng JW; Mehra MR
    Vasc Health Risk Manag; 2013; 9():245-54. PubMed ID: 23696706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
    Goldstein JL; Whellan DJ; Scheiman JM; Cryer BL; Eisen GM; Lanas A; Fort JG
    Cardiovasc Ther; 2016 Apr; 34(2):59-66. PubMed ID: 26725920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
    Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA
    Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence of co-administration of clopidogrel and proton pump inhibitors.
    Shrestha K; Hughes JD; Lee YP; Parsons R
    Qual Prim Care; 2011; 19(1):35-42. PubMed ID: 21703110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuries.
    Mo C; Sun G; Lu ML; Zhang L; Wang YZ; Sun X; Yang YS
    World J Gastroenterol; 2015 May; 21(17):5382-92. PubMed ID: 25954113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
    Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
    Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on oral antiplatelet drug interactions with proton pump inhibitors: what are the risks?
    Jourdi G; Hulot JS; Gaussem P
    Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):749-764. PubMed ID: 38980768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
    Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
    García-Rayado G; Sostres C; Lanas A
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):875-888. PubMed ID: 28463532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
    Sharma T; Bliden K; Chaudhary R; Tantry U; Gurbel PA
    Expert Opin Pharmacother; 2017 Jan; 18(1):123-131. PubMed ID: 27937054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining aspirin and proton pump inhibitors: for whom the warning bell tolls?
    Würtz M; Grove EL
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1051-5. PubMed ID: 22834712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease.
    Kagolanu D; Sayedy N; Haseeb S; Shah S; Lam P; Munnangi S; Viswanathan P; Stephenson K
    Am J Cardiol; 2017 Oct; 120(7):1118-1121. PubMed ID: 28803655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinitiating aspirin therapy for primary prevention of cardiovascular events in a patient post-aspirin-induced upper gastrointestinal bleed: a case report and review of literature.
    Adly G; Plakogiannis R
    Ann Pharmacother; 2013 Feb; 47(2):e8. PubMed ID: 23386069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
    Hsu PI
    J Gastroenterol Hepatol; 2012 Apr; 27(4):654-61. PubMed ID: 22283743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
    Sung JJ; Lau JY; Ching JY; Wu JC; Lee YT; Chiu PW; Leung VK; Wong VW; Chan FK
    Ann Intern Med; 2010 Jan; 152(1):1-9. PubMed ID: 19949136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
    de Groot NL; van Haalen HG; Spiegel BM; Laine L; Lanas A; Focks JJ; Siersema PD; van Oijen MG
    Cardiovasc Drugs Ther; 2013 Aug; 27(4):341-57. PubMed ID: 23417566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.